- Pharma Industry
- 1 min read
Merck's endometrial cancer therapy fails trial
The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in patients with high-risk endometrial cancer after surgery.
Read by
The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in patients with high-risk endometrial cancer after surgery.
The study's other main goal of overall survival was not formally tested since the trial failed in showing significant disease-free survival.
Endometrial cancer begins in the inner lining of the uterus, or endometrium, and is the most common type of the disease affecting the organ.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta and Shilpi Majumdar)
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions